Estrogen enhances basal nitric oxide release in the forearm vasculature in perimenopausal women

Krishnankutty Sudhir, Garry L. Jennings, John W. Funder, Paul A. Komesaroff

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The mechanisms of estrogen-induced cardiovascular protection are incompletely understood. Acute estrogen administration enhances acetylcholine-induced vasorelaxation, suggesting that endothelium-dependent factors may be important. The effect of long term estrogen supplementation on endothelial function has not been well defined. In this double-blind, randomized study, we examined endothelial function in forearm resistance arteries in 11 perimenopausal women before and after 8 weeks of estrogen supplementation (estradiol valerate, 2 mg daily, n=6) or placebo (n=5). Forearm blood flow was measured by venous-occlusion plethysmography, and vasoactive agents were infused through a brachial artery cannula in doses that did not influence blood pressure or heart rate. Estrogen supplementation significantly reduced systolic and diastolic pressures but had no effect on plasma lipoproteins. Estrogen did not alter the vasodilator responses to acetylcholine at doses of 9.25, 18.5, and 37 μg/min (rise in forearm blood flow before estrogen: 263±72%, 288±66%, and 383±84%, respectively; after estrogen: 205±34%, 260±44%, and 359±54%, P>.05.). Vasodilator responses to the endothelium-independent agent sodium nitroprusside (1.6 μg/min) were also unchanged after estrogen supplementation. However, estrogen enhanced vasoconstrictor responses to the nitric oxide synthase inhibitor N(G)- monomethyl-L-arginine at doses of 1, 2, and 4 μmol/min (fall in forearm blood flow before estrogen: 13±9%, 20±7%, and 26±8%, respectively: after estrogen: 18±9%, 36±7%, and 47±7%, P=.04). Responses to vasoactive agents were unchanged after administration of placebo. Thus, in perimenopausal women, estrogen supplementation reduces blood pressure and enhances basal but not acetylcholine-induced nitric oxide release in forearm resistance arteries.

Original languageEnglish
Pages (from-to)330-334
Number of pages5
JournalHypertension
Volume28
Issue number3
DOIs
Publication statusPublished - 1 Jan 1996
Externally publishedYes

Keywords

  • endothelium, vascular
  • estrogens
  • menopause
  • nitric oxide
  • plethysmography

Cite this

@article{99e2aab27dec40beaab809c3d429b07e,
title = "Estrogen enhances basal nitric oxide release in the forearm vasculature in perimenopausal women",
abstract = "The mechanisms of estrogen-induced cardiovascular protection are incompletely understood. Acute estrogen administration enhances acetylcholine-induced vasorelaxation, suggesting that endothelium-dependent factors may be important. The effect of long term estrogen supplementation on endothelial function has not been well defined. In this double-blind, randomized study, we examined endothelial function in forearm resistance arteries in 11 perimenopausal women before and after 8 weeks of estrogen supplementation (estradiol valerate, 2 mg daily, n=6) or placebo (n=5). Forearm blood flow was measured by venous-occlusion plethysmography, and vasoactive agents were infused through a brachial artery cannula in doses that did not influence blood pressure or heart rate. Estrogen supplementation significantly reduced systolic and diastolic pressures but had no effect on plasma lipoproteins. Estrogen did not alter the vasodilator responses to acetylcholine at doses of 9.25, 18.5, and 37 μg/min (rise in forearm blood flow before estrogen: 263±72{\%}, 288±66{\%}, and 383±84{\%}, respectively; after estrogen: 205±34{\%}, 260±44{\%}, and 359±54{\%}, P>.05.). Vasodilator responses to the endothelium-independent agent sodium nitroprusside (1.6 μg/min) were also unchanged after estrogen supplementation. However, estrogen enhanced vasoconstrictor responses to the nitric oxide synthase inhibitor N(G)- monomethyl-L-arginine at doses of 1, 2, and 4 μmol/min (fall in forearm blood flow before estrogen: 13±9{\%}, 20±7{\%}, and 26±8{\%}, respectively: after estrogen: 18±9{\%}, 36±7{\%}, and 47±7{\%}, P=.04). Responses to vasoactive agents were unchanged after administration of placebo. Thus, in perimenopausal women, estrogen supplementation reduces blood pressure and enhances basal but not acetylcholine-induced nitric oxide release in forearm resistance arteries.",
keywords = "endothelium, vascular, estrogens, menopause, nitric oxide, plethysmography",
author = "Krishnankutty Sudhir and Jennings, {Garry L.} and Funder, {John W.} and Komesaroff, {Paul A.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1161/01.HYP.28.3.330",
language = "English",
volume = "28",
pages = "330--334",
journal = "Hypertension",
issn = "0194-911X",
publisher = "American Heart Association",
number = "3",

}

Estrogen enhances basal nitric oxide release in the forearm vasculature in perimenopausal women. / Sudhir, Krishnankutty; Jennings, Garry L.; Funder, John W.; Komesaroff, Paul A.

In: Hypertension, Vol. 28, No. 3, 01.01.1996, p. 330-334.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Estrogen enhances basal nitric oxide release in the forearm vasculature in perimenopausal women

AU - Sudhir, Krishnankutty

AU - Jennings, Garry L.

AU - Funder, John W.

AU - Komesaroff, Paul A.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - The mechanisms of estrogen-induced cardiovascular protection are incompletely understood. Acute estrogen administration enhances acetylcholine-induced vasorelaxation, suggesting that endothelium-dependent factors may be important. The effect of long term estrogen supplementation on endothelial function has not been well defined. In this double-blind, randomized study, we examined endothelial function in forearm resistance arteries in 11 perimenopausal women before and after 8 weeks of estrogen supplementation (estradiol valerate, 2 mg daily, n=6) or placebo (n=5). Forearm blood flow was measured by venous-occlusion plethysmography, and vasoactive agents were infused through a brachial artery cannula in doses that did not influence blood pressure or heart rate. Estrogen supplementation significantly reduced systolic and diastolic pressures but had no effect on plasma lipoproteins. Estrogen did not alter the vasodilator responses to acetylcholine at doses of 9.25, 18.5, and 37 μg/min (rise in forearm blood flow before estrogen: 263±72%, 288±66%, and 383±84%, respectively; after estrogen: 205±34%, 260±44%, and 359±54%, P>.05.). Vasodilator responses to the endothelium-independent agent sodium nitroprusside (1.6 μg/min) were also unchanged after estrogen supplementation. However, estrogen enhanced vasoconstrictor responses to the nitric oxide synthase inhibitor N(G)- monomethyl-L-arginine at doses of 1, 2, and 4 μmol/min (fall in forearm blood flow before estrogen: 13±9%, 20±7%, and 26±8%, respectively: after estrogen: 18±9%, 36±7%, and 47±7%, P=.04). Responses to vasoactive agents were unchanged after administration of placebo. Thus, in perimenopausal women, estrogen supplementation reduces blood pressure and enhances basal but not acetylcholine-induced nitric oxide release in forearm resistance arteries.

AB - The mechanisms of estrogen-induced cardiovascular protection are incompletely understood. Acute estrogen administration enhances acetylcholine-induced vasorelaxation, suggesting that endothelium-dependent factors may be important. The effect of long term estrogen supplementation on endothelial function has not been well defined. In this double-blind, randomized study, we examined endothelial function in forearm resistance arteries in 11 perimenopausal women before and after 8 weeks of estrogen supplementation (estradiol valerate, 2 mg daily, n=6) or placebo (n=5). Forearm blood flow was measured by venous-occlusion plethysmography, and vasoactive agents were infused through a brachial artery cannula in doses that did not influence blood pressure or heart rate. Estrogen supplementation significantly reduced systolic and diastolic pressures but had no effect on plasma lipoproteins. Estrogen did not alter the vasodilator responses to acetylcholine at doses of 9.25, 18.5, and 37 μg/min (rise in forearm blood flow before estrogen: 263±72%, 288±66%, and 383±84%, respectively; after estrogen: 205±34%, 260±44%, and 359±54%, P>.05.). Vasodilator responses to the endothelium-independent agent sodium nitroprusside (1.6 μg/min) were also unchanged after estrogen supplementation. However, estrogen enhanced vasoconstrictor responses to the nitric oxide synthase inhibitor N(G)- monomethyl-L-arginine at doses of 1, 2, and 4 μmol/min (fall in forearm blood flow before estrogen: 13±9%, 20±7%, and 26±8%, respectively: after estrogen: 18±9%, 36±7%, and 47±7%, P=.04). Responses to vasoactive agents were unchanged after administration of placebo. Thus, in perimenopausal women, estrogen supplementation reduces blood pressure and enhances basal but not acetylcholine-induced nitric oxide release in forearm resistance arteries.

KW - endothelium, vascular

KW - estrogens

KW - menopause

KW - nitric oxide

KW - plethysmography

UR - http://www.scopus.com/inward/record.url?scp=0029816542&partnerID=8YFLogxK

U2 - 10.1161/01.HYP.28.3.330

DO - 10.1161/01.HYP.28.3.330

M3 - Article

VL - 28

SP - 330

EP - 334

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 3

ER -